Whole-Genome Sequencing (WGS) Test: DNA Variants, Disease Risk, and Results

Whole-genome sequencing (WGS) examines nearly all of a person’s DNA in a single test. Unlike tests limited to one gene, a gene panel, or the protein-coding regions of the genome, WGS can evaluate coding and many noncoding regions while also looking for several kinds of DNA changes. That broad reach can be especially useful when symptoms do not point to one clear diagnosis, previous genetic testing was unrevealing, or a condition may be caused by a structural or regulatory variant. Yet “whole genome” does not mean that every possible genetic change will be detected or understood. The clinical value of WGS depends on the laboratory’s methods, the reason for testing, the quality of the sample, the analysis strategy, and how well current medical knowledge connects a variant to disease. Results may provide a diagnosis, narrow future testing, reveal an uncertain finding, or remain negative despite a genetic cause.

• WGS surveys most coding and noncoding DNA rather than only selected genes.
• It can detect many single-letter changes, small insertions or deletions, copy-number changes, and structural variants.
• A positive result must fit the person’s symptoms, inheritance pattern, and clinical history.
• A negative result does not exclude every genetic condition or every type of variant.
• Secondary findings, privacy, family implications, and reanalysis should be discussed before testing.

Table of Contents

• What Whole-Genome Sequencing Examines
• When WGS May Be Used
• How WGS Is Performed and Analyzed
• What WGS Results Can Mean
• How WGS Relates to Disease Risk
• Limitations and Variants WGS Can Miss
• Secondary Findings, Privacy, and Next Steps

What Whole-Genome Sequencing Examines

The human genome contains about three billion DNA letters. Only a small fraction directly encodes proteins, but the rest is not simply empty space. Noncoding DNA includes regulatory regions, introns within genes, repetitive sequences, and other elements that can influence when, where, and how genes function. WGS is designed to read across most of this material rather than restricting analysis to a predetermined set of genes.

In routine clinical use, WGS commonly relies on short-read sequencing. DNA is broken into many small fragments, the fragments are sequenced, and computer programs align the reads to a reference genome. The laboratory then identifies positions where the tested person’s sequence differs from the reference. Those differences are called variants. Most are harmless parts of human diversity. The challenge is to determine whether any variant plausibly explains the medical question that prompted testing.

A clinical WGS pipeline may look for several variant classes:

• Single-nucleotide variants, in which one DNA letter differs.
• Small insertions and deletions, often called indels.
• Copy-number variants, involving deleted or duplicated DNA segments.
• Structural variants, such as larger deletions, duplications, inversions, translocations, or complex rearrangements.
• Some repeat expansions, depending on the locus, read length, software, and validation method.
• Mitochondrial DNA variants, if mitochondrial analysis is included and validated by the laboratory.
• Mosaic variants, when the altered DNA is present in only a fraction of sampled cells and the variant level is high enough to detect.

The test’s name does not guarantee that every laboratory evaluates all of these categories equally. Some WGS assays are optimized mainly for small sequence variants and copy-number changes. Others add validated analysis for structural variants, mitochondrial DNA, pharmacogenomic markers, or selected repeat disorders. A clinician should review the laboratory’s test description rather than assuming that “whole genome” means unlimited analysis.

WGS differs from whole-exome sequencing, which concentrates on coding exons and nearby splice regions. WGS offers broader, often more even coverage and may support integrated structural-variant analysis. Yet a noncoding variant is useful only when evidence links it to altered gene function and the person’s condition.

Clinical analysis is therefore narrower than raw data generation. A laboratory may sequence the genome broadly but prioritize interpretation of genes and regions relevant to the person’s features. This focused approach reduces the number of irrelevant findings and directs expert review toward variants with a realistic chance of explaining the case.

When WGS May Be Used

WGS is most often considered for diagnostic evaluation rather than as a general health scan. It can be particularly valuable when a person has a suspected genetic disorder but the phenotype is complex, genetically heterogeneous, or not specific enough to select a single gene test.

Common clinical situations include:

• A child or adult with developmental differences, congenital anomalies, neurologic symptoms, metabolic findings, immune problems, or another unexplained multisystem condition.
• A severe disorder beginning in infancy, especially when a rapid diagnosis could change treatment, surveillance, or intensive-care decisions.
• A family with multiple affected relatives but no known molecular diagnosis.
• A suspected condition that may result from many different genes or several variant types.
• Previous chromosome testing, microarray, single-gene testing, a multigene panel, or exome sequencing that did not find an explanation.
• A need to consolidate several possible tests into one broad analysis when time or sample volume is limited.

In critically ill infants and children, rapid WGS may replace slow sequential testing. A molecular diagnosis can guide medication, nutrition, surveillance, invasive procedures, or goals-of-care decisions. It may also end a long diagnostic search even when no targeted treatment exists.

For adults with longstanding unexplained symptoms, WGS may reveal that apparently unrelated findings share one cause or establish a diagnosis relevant to relatives. Yield depends heavily on the phenotype, family structure, prior testing, and medical records.

Diagnostic WGS should be distinguished from screening in people without symptoms. A variant that explains a strongly matching phenotype may be highly informative diagnostically, while the same variant in an asymptomatic person may require more caution because penetrance, age, environment, and family history affect whether disease will occur.

WGS is not always the best first test. A targeted assay may be more sensitive, faster, less expensive, or easier to interpret when the suspected disorder is clear. For example, some repeat-expansion diseases, methylation disorders, low-level mosaic conditions, or disorders caused by a known familial variant are better evaluated with specialized testing. A focused test can also provide stronger coverage of technically difficult regions.

The decision should begin with the clinical question: Is the goal to diagnose current symptoms, estimate future risk, identify carrier status, guide reproductive planning, or examine a tumor? WGS performed on blood or saliva usually evaluates constitutional or germline DNA. It is not a substitute for somatic tumor testing, which looks for changes acquired by cancer cells and often requires tumor tissue.

How WGS Is Performed and Analyzed

WGS usually begins with a blood sample, although saliva, buccal cells, cultured cells, or another specimen may be accepted. Blood often provides high-quality DNA and is useful for many constitutional conditions. The most appropriate sample can change when mosaicism, a blood disorder, prior bone marrow transplantation, or tissue-specific disease is suspected.

After sequencing, automated systems generate millions or billions of reads and compare them with a reference genome. Quality-control steps assess whether enough of the genome was read at sufficient depth, whether the sample may be contaminated or mislabeled, and whether the data support reliable variant calls. The laboratory then filters and prioritizes variants using several kinds of evidence:

• The person’s symptoms, age of onset, laboratory findings, imaging, and physical features.
• The known function of affected genes.
• Published reports and curated disease databases.
• Population frequency: variants common in healthy populations are less likely to cause a rare severe disorder.
• Predicted or demonstrated effect on RNA or protein function.
• Inheritance pattern and whether the variant is new in the affected person.
• Whether the variant segregates with disease in relatives.
• Technical quality and confirmation with another method when required.

Detailed clinical information matters because every genome contains millions of variants. A requisition that simply says “developmental delay” provides less interpretive power than a structured description of growth, neurologic signs, congenital findings, family history, and prior test results. Some programs translate clinical features into standardized phenotype terms so software and laboratory scientists can rank genes more accurately.

Testing a child together with both biological parents is called trio WGS. Trio analysis can show whether a variant was inherited or occurred de novo, meaning it is present in the child but not detected in either parent’s tested sample. This can sharply reduce the number of plausible variants, especially for severe early-onset disorders. It can also determine whether two variants in the same recessive-disease gene are on opposite parental copies of the chromosome, a relationship known as being in trans.

Duo testing includes one relative, and singleton testing analyzes only the affected person. Singleton WGS may still be useful, but it can leave more uncertainty. Additional relatives may be tested later to clarify whether a candidate variant tracks with the condition.

The laboratory may use a virtual panel: the whole genome is sequenced, but interpretation initially focuses on genes related to the phenotype. Broader review can follow if that pass is negative. Turnaround ranges from days in selected rapid programs to weeks or months for standard testing, and preliminary urgent findings may require later confirmation.

Before ordering, clinicians should clarify whether the laboratory reports secondary findings, carrier findings, pharmacogenomic variants, or polygenic risk scores. These are separate choices, not automatic components of every WGS test. Consent should also address whether the raw data will be stored, whether reanalysis is available, and whether family samples may reveal unexpected biological relationships.

What WGS Results Can Mean

A WGS report may be positive, negative, uncertain, partially explanatory, or complex. The report language should be interpreted in relation to the testing indication rather than as a universal verdict about health.

A positive or diagnostic result identifies one or more pathogenic or likely pathogenic variants that fit the person’s condition and the gene’s inheritance pattern. For a dominant disorder, one disease-causing variant may be sufficient. A recessive diagnosis usually requires two relevant variants affecting both gene copies. An X-linked or mitochondrial condition follows a different inheritance pattern. The laboratory and clinician should assess whether the genotype explains all major findings or only part of the presentation.

A positive result may change:

• The name and expected course of the condition.
• Medication or dietary decisions.
• Screening for complications.
• Eligibility for a specialist clinic, clinical trial, or targeted therapy.
• Testing recommendations for parents, siblings, children, or other relatives.
• Recurrence-risk counseling for future pregnancies.

A negative result means that the laboratory did not find a reportable variant that explains the indication under the methods and knowledge available at the time. It does not prove that the condition is not genetic. The causal variant may be in a difficult region, belong to a variant class the assay does not reliably detect, involve a gene not yet linked to disease, or be filtered out because the clinical features were incomplete. The person may also have a multifactorial condition caused by many genes plus environmental influences.

An uncertain result often involves a variant of uncertain significance, or VUS. A VUS has insufficient or conflicting evidence for classification as disease-causing or benign. It should not be treated as a confirmed diagnosis, used alone to direct irreversible treatment, or used by itself for predictive testing in healthy relatives. Family studies can sometimes provide evidence, but relatives should not be tested merely to learn whether they share an uninterpretable variant without a clear plan for how the information will be used. More detail is available in the guide to VUS results and reclassification.

A candidate finding may involve a gene not yet firmly linked to disease or a noncoding variant with incomplete evidence. Some laboratories report selected candidates; others reserve them for research. The finding may gain meaning as additional patients or functional evidence emerge.

A partial or blended diagnosis is possible when one finding explains some features but not others. A person can have more than one genetic condition. WGS is well suited to detecting blended phenotypes because analysis is not confined to one organ system, but recognizing them still requires careful clinical correlation.

Reports may also include secondary findings unrelated to the original symptoms but considered medically actionable. These should be clearly separated from the primary diagnostic result. Carrier findings, pharmacogenomic information, and risk alleles should likewise be labeled according to their distinct meaning.

Variant classification can change as evidence improves. The report date, reference transcript, genome build, and laboratory criteria matter when comparing interpretations over time.

How WGS Relates to Disease Risk

WGS can reveal variants associated with disease risk, but the word “risk” covers several fundamentally different situations. A highly penetrant pathogenic variant in a well-established disease gene may confer a substantial probability of developing a condition. A recessive carrier variant may have little or no effect on the tested person’s health but matter for reproductive planning. A common variant may alter risk only slightly. A polygenic score may combine many common markers into a relative-risk estimate. These findings should not be blended into one category.

For diagnostic testing, the central question is usually whether a variant explains existing symptoms. The same report may also indicate risks that extend beyond the current presentation. For example, a molecular diagnosis can identify complications that have not yet appeared and prompt surveillance. The strength of that prediction depends on penetrance, variable expression, age, sex-related biology, environment, medical care, and the person’s specific variant.

Penetrance is the proportion of people with a genotype who develop the associated trait. Complete penetrance is uncommon across all genetic conditions. Variable expression means that people with the same disease-causing variant can have different symptoms or severity. Therefore, even a confirmed pathogenic finding may not predict exactly when disease will begin or how serious it will be.

Family history modifies interpretation but has limits. A pathogenic variant may appear in a family with few affected relatives because of small family size, young ages, a de novo event, reduced penetrance, or incomplete records. A strong family history can also remain unexplained after negative WGS.

WGS is sometimes marketed to estimate future disease risk in healthy people, but usefulness varies. An actionable monogenic finding may support established prevention, carrier results can inform reproductive choices, and selected pharmacogenomic variants may guide medication decisions. Common-disease associations usually have smaller effects and require integration with age, ancestry, clinical measurements, and standard risk tools.

A polygenic risk score is not simply the “rest” of a WGS result. It requires a validated scoring model, a defined population, appropriate ancestry calibration, and evidence that using the score improves care. A raw genome file does not automatically yield a clinically valid score for every disease.

Risk findings can affect relatives because germline variants are shared within families. A confirmed pathogenic result may lead to targeted testing of relatives, which is usually more accurate and less expensive than repeating broad WGS. Relatives should receive the exact laboratory report or variant description so testing is aimed at the correct change. A genetics professional can help distinguish who is at risk, what test is appropriate, and what a negative targeted result would mean.

Limitations and Variants WGS Can Miss

WGS is broad, but it is not technically or medically complete. Short-read sequencing can struggle in regions with highly similar sequences, extreme GC content, long repeats, pseudogenes, segmental duplications, or complex structural variation. Reads may map to the wrong location or fail to span the entire altered region.

Important limitations can include:

• Repeat expansions: Some expansions can be suggested by WGS, but many require a dedicated assay to size the repeat, assess interruptions, or detect very large expansions reliably.
• Methylation and imprinting disorders: Standard DNA sequencing does not directly measure methylation patterns. Conditions such as certain imprinting syndromes may need methylation-specific testing.
• Balanced rearrangements: WGS may detect many inversions and translocations, but sensitivity varies with breakpoint location, repeat content, and analysis pipeline.
• Low-level mosaicism: A variant present in a small percentage of cells may fall below detection thresholds. Blood may not contain the variant even when another tissue does.
• Pseudogene-rich regions: Genes with highly similar copies can require specialized methods or long-read sequencing.
• Large or complex repeat-rich structural variants: Short fragments may not reveal the full configuration.
• Mitochondrial heteroplasmy: Detection depends on whether mitochondrial DNA is analyzed, sequencing depth, tissue choice, and the fraction of altered mitochondrial genomes.
• RNA-splicing effects: WGS may identify a candidate DNA variant, but RNA studies can be needed to prove abnormal splicing or gene expression.
• Epigenetic changes: DNA sequence may be normal even when gene regulation is disrupted through an epigenetic mechanism.

A negative report can also reflect interpretation limits rather than sequencing limits. Scientists do not yet know the function of every gene or regulatory element. Many noncoding variants are detected, but only a small portion can be confidently linked to disease. Laboratories may therefore restrict reporting to variants with strong evidence.

Coverage is uneven: an average such as 30-times coverage does not mean every base was read 30 times. Laboratory documentation may identify poorly covered regions or explain whether gaps are filled by another method.

The sample source matters. Blood WGS may miss variants confined to another tissue, so suspected mosaic or tissue-specific disease may require fibroblasts or affected tissue. Hematologic malignancy, clonal hematopoiesis, or stem-cell transplantation can also complicate germline interpretation from blood.

WGS can generate false-positive candidate calls that fail confirmation, especially for difficult structural variants or low-level mosaic findings. It can also generate false negatives when the analytic pipeline does not call or prioritize the causal variant. Orthogonal confirmation—using a different laboratory method—may be recommended before medical decisions or family testing.

Long-read sequencing can resolve some repeats and complex rearrangements that short reads cannot, but availability, validation, cost, and interpretation still vary. Not every test labeled WGS uses the same technology.

Secondary Findings, Privacy, and Next Steps

Because WGS surveys so much DNA, pretest counseling should address information beyond the original diagnostic question. Some laboratories follow professional recommendations to offer analysis of a defined list of genes associated with preventable or treatable conditions. These secondary findings may involve hereditary cancer or cardiovascular risk, among other areas. The eligible gene list and opt-out policy can change, so patients should review the current laboratory consent rather than relying on a general description.

A secondary finding is not the same as an incidental observation. A secondary finding is actively sought according to a policy, while an incidental finding is encountered unexpectedly during analysis. Laboratories differ in what they search for and report. Testing children raises additional questions about whether findings concern childhood-onset disease, adult-onset risk, or the health of a parent.

WGS can also reveal unexpected family relationships, such as nonpaternity, donor conception, or previously unknown biological relatives, especially in trio or family testing. Consent should explain how the laboratory handles these situations and whether results that affect sample interpretation will be disclosed.

Genome data are uniquely identifying and may remain informative for decades. Patients should ask where data and samples will be stored, how long they will be retained, whether research sharing is optional, who can access the health record, and which genetic-discrimination protections apply. Security cannot eliminate all risk, although responsible data sharing can improve variant interpretation by enabling comparison across patients.

After results are issued, next steps depend on the finding. A positive result may lead to specialist referral, baseline evaluations, targeted testing of relatives, and a care plan. An uncertain result may prompt testing of selected family members, review of clinical features, or functional studies. A negative result may lead to targeted assays for a suspected blind spot, testing of another tissue, RNA sequencing, methylation studies, long-read sequencing, or research enrollment.

Reanalysis is one of the most important features of genome data. New gene-disease relationships are discovered, variant databases expand, and classification frameworks improve. Reanalysis may be initiated by the laboratory at set intervals, requested by the clinician, or performed only when new clinical information emerges. Patients should ask who is responsible for requesting it, whether there is a fee, whether new consent is needed, and how updated results will be communicated.

New symptoms, imaging findings, or family diagnoses may allow previously overlooked variants to be reprioritized, so the genetics team should receive meaningful clinical updates.

WGS is best understood as a powerful diagnostic platform, not a single definitive answer. Its strength comes from combining broad DNA analysis with careful clinical evaluation, family information, specialized confirmation, and periodic reinterpretation. The most useful report is one that answers a clearly defined question and leads to an appropriate medical or reproductive decision.

References

1. Genome Sequencing for Diagnosing Rare Diseases
2. Diagnostic Yield of Genome Sequencing Compared With Exome Sequencing: A Systematic Review and Meta-Analysis
3. Access to Clinical Genome Sequencing for Rare Disease Diagnosis
4. Implementation of Whole-Genome Sequencing in Clinical Practice
5. American College of Medical Genetics and Genomics Practice Guidelines
6. What Are Whole Exome Sequencing and Whole Genome Sequencing?

Disclaimer

This article provides general education about clinical whole-genome sequencing and does not replace individualized medical advice, genetic counseling, or interpretation by the testing laboratory. The appropriate test, specimen, consent choices, and follow-up depend on the person’s symptoms, family history, and the laboratory’s validated methods. Do not make treatment, surveillance, or reproductive decisions from raw genomic data or a variant result without qualified clinical review.